Approval of Un-audited financial results for the quarter ended December 31, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.8 pts more than Nifty Microcap 250 and 1.5 pts more than its Personal Care peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The board approved unaudited Q3 FY26 results showing net sales of just Rs. 7.96 lakhs, down sharply from Rs. 63.43 lakhs in Q3 FY25 — a drop of about 87% quarter-on-quarter. Nine-month net sales also fell to Rs. 74.45 lakhs from Rs. 152.35 lakhs last year. Despite the weak operating performance, the company reported a standalone profit after tax of Rs. 34.55 lakhs for the quarter (vs a loss of Rs. 10.61 lakhs in Q3 FY25), driven almost entirely by a sharp spike in other income of Rs. 75.21 lakhs (vs Rs. 1.11 lakhs a year ago). On a nine-month basis, the company is still in the red, with a standalone loss of Rs. 32.36 lakhs and a consolidated loss of Rs. 34.10 lakhs. The auditor (Praveen & Madan) issued an unmodified review report on both standalone and consolidated results, with no qualifications.
The headline quarterly profit is misleading — it is propped up entirely by one-time other income, while the core personal care business continues to shrink and remains loss-making. Shareholders should watch whether the other income is a genuine recurring source or a one-off, and monitor sales recovery, as the 9-month loss persists on a consolidated basis.